Tags

Type your tag names separated by a space and hit enter

Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study.
J Asthma. 1998; 35(2):153-64.JA

Abstract

Dose-response relationships with inhaled corticosteroids in the treatment of asthma have been difficult to establish. A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma. Methacholine challenge testing was conducted in addition to measurement of traditional efficacy variables. After a single-blind screening period, 138 patients > or = 12 years of age were randomly assigned to receive placebo, FP 50 microg, or FP 100 microg, twice daily for 8 weeks. The results of methacholine challenge testing averaged over all visits favored FP 200 microg/day over placebo and FP 100 microg/day (p < 0.05); there were no significant differences between placebo and FP 100 microg/day. Mean changes from baseline to endpoint favored each dose of FP over placebo based on forced expiratory volume in 1 sec (FEV1), patient-measured peak expiratory flow (PEF), total symptom scores, and rescue bronchodilator use (p < 0.05); there were no differences in these parameters between the two doses of FP. The addition of methacholine challenge testing allowed definition of a dose-response relationship that was not apparent with traditional efficacy variables.

Authors+Show Affiliations

Allergy Associates Research Office, Portland, Oregon 97213, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9576141

Citation

Noonan, M J., et al. "Dose-related Response to Inhaled Fluticasone Propionate in Patients With Methacholine-induced Bronchial Hyperresponsiveness: a Double-blind, Placebo-controlled Study." The Journal of Asthma : Official Journal of the Association for the Care of Asthma, vol. 35, no. 2, 1998, pp. 153-64.
Noonan MJ, Chervinsky P, Wolfe J, et al. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. J Asthma. 1998;35(2):153-64.
Noonan, M. J., Chervinsky, P., Wolfe, J., Liddle, R., Kellerman, D. J., & Crescenzi, K. L. (1998). Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. The Journal of Asthma : Official Journal of the Association for the Care of Asthma, 35(2), 153-64.
Noonan MJ, et al. Dose-related Response to Inhaled Fluticasone Propionate in Patients With Methacholine-induced Bronchial Hyperresponsiveness: a Double-blind, Placebo-controlled Study. J Asthma. 1998;35(2):153-64. PubMed PMID: 9576141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. AU - Noonan,M J, AU - Chervinsky,P, AU - Wolfe,J, AU - Liddle,R, AU - Kellerman,D J, AU - Crescenzi,K L, PY - 1998/5/12/pubmed PY - 1998/5/12/medline PY - 1998/5/12/entrez SP - 153 EP - 64 JF - The Journal of asthma : official journal of the Association for the Care of Asthma JO - J Asthma VL - 35 IS - 2 N2 - Dose-response relationships with inhaled corticosteroids in the treatment of asthma have been difficult to establish. A multicenter, double-blind, parallel-group study was conducted to evaluate the clinical efficacy and safety of low doses of inhaled fluticasone propionate (FP) in patients with mild to moderate asthma. Methacholine challenge testing was conducted in addition to measurement of traditional efficacy variables. After a single-blind screening period, 138 patients > or = 12 years of age were randomly assigned to receive placebo, FP 50 microg, or FP 100 microg, twice daily for 8 weeks. The results of methacholine challenge testing averaged over all visits favored FP 200 microg/day over placebo and FP 100 microg/day (p < 0.05); there were no significant differences between placebo and FP 100 microg/day. Mean changes from baseline to endpoint favored each dose of FP over placebo based on forced expiratory volume in 1 sec (FEV1), patient-measured peak expiratory flow (PEF), total symptom scores, and rescue bronchodilator use (p < 0.05); there were no differences in these parameters between the two doses of FP. The addition of methacholine challenge testing allowed definition of a dose-response relationship that was not apparent with traditional efficacy variables. SN - 0277-0903 UR - https://www.unboundmedicine.com/medline/citation/9576141/Dose_related_response_to_inhaled_fluticasone_propionate_in_patients_with_methacholine_induced_bronchial_hyperresponsiveness:_a_double_blind_placebo_controlled_study_ L2 - http://www.tandfonline.com/doi/full/10.3109/02770909809068203 DB - PRIME DP - Unbound Medicine ER -